showed a trendP = 0.059
Glycemic parameters, including HbA 1c , FPG, and PPG, were assessed at baseline and assessed by the end of the treatment.[ 29 ] The primary endpoint showed a trend toward lower levels of HbA 1c by week 12 in patients receiving triple FDC vs. insulin plus metformin (-1.33% vs. -0.83%; P = 0.059).